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Abstract Using a phage display peptide library, we character-
ized the epitope of two monoclonal antibodies reacting with
syndecan-1: B-B2 and B-B4. The identified epitopes QDIT, for
B-B2, and LPEV, for B-B4, were found to align with residues
36^39 and 90^93 of the mature protein, respectively. In contrast
to B-B4, the B-B2 epitope is close to a potential glycosami-
noglycan attachment site. Since syndecan-1 is heavily glycosy-
lated and post-translational modifications are cell type specific,
these results might explain the differences observed in the
reactivity pattern of B-B2 and B-B4 and suggest that these
monoclonal antibodies are useful probes to study cell surface
exposed syndecan-1.
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1. Introduction
Two monoclonal antibodies (mAbs), B-B2 and B-B4, which
speci¢cally identify the human plasma cell among hemopoietic
cells were previously developed [1]. These mAbs appeared to
be useful tools for multiple myeloma pathology identi¢cation
involving terminally di¡erentiated B-cells [2,3]. B-B4 has also
been used to isolate pure populations of myeloma cells from
bone marrow samples of such patients [4,5]. This mAb does
not react with acute lymphocytic leukemia and chronic lym-
phoblastic leukemia cells [2] which are less di¡erentiated B-
cells, but it reacts with Reed-Sternberg cells of classical Hodg-
kin’s disease [6]. By expression cloning the antigen recognized
by B-B4 was shown to be syndecan-1 [2], which de¢nes the
new CD138 cluster of leukocyte di¡erentiation [7]. This mol-
ecule was originally cloned from mammalian epithelial cell
lines of mouse and human origin [8,9]. For reviews of synde-
can-1 see [10^15]. Brie£y, in mature tissues syndecan-1 is con-
stitutively expressed by epithelial cells. However, syndecan-1
expression is regulated during embryogenesis, wound healing
and carcinogenesis. In response to wound healing, syndecan-1
expression is induced in sprouting and proliferating endothe-
lial cells and in proliferating keratinocytes [16]. In malignan-
cies its expression can also be altered. It is suppressed upon
malignant transformation of human keratinocytes [17], and
an association between syndecan-1 expression by squamous
cell carcinoma of the head and neck and clinical outcome
has been observed [18]. In mice, syndecan-1 is expressed by
maturing B-cells and plasmocytes but not by circulating B-
cells [19]. Di¡erent roles have been suggested for syndecan-1
such as in proliferation and adhesion.
To better characterize B-B2 and B-B4 mAbs reacting with
syndecan-1 transfected COS-7 cells and displaying similar but
not identical patterns of recognition with cell lines [2], it was
attempted to identify their epitopes by using the phage display
technology. This technology is a powerful approach to study
protein-protein interactions. Originally, peptides were ex-
pressed as fusion proteins to the minor coat protein pIII of
the bacteriophages, therefore enabling large libraries to be
screened by a⁄nity puri¢cation of the modi¢ed phage par-
ticles [20,21]. The display has been extended to proteins like
antibody fragments [22^24]. Here we used the phage peptide
approach to characterize the epitopes of B-B2 and of B-B4
mAbs. The results allowed us to localize exactly their interact-
ing site on syndecan-1 core protein.
2. Materials and methods
2.1. MAbs and synthetic peptides
B-B2 and B-B4 mAbs were produced by ascitic £uid and puri¢ed on
a protein A column. The isotype of B-B2 is IgG2b and that of B-B4
IgG1. The synthetic peptides were assembled automatically by step-
wise Fmoc-t-butyl solid phase synthesis in a Synergy Appl. The puri-
¢ed materials were then characterized by amino acid composition,
sequence analysis [25] and laser desorption [26].
2.2. Selection of phage peptides
The library (Biolabs) expressing random unconstrained heptapep-
tides fused to the N-terminus of pIII consists of 2U109 clones. This
diversity is close to the theoretical number of combinations for an
amino acid heptamer. For panning the mAbs were coated at 50 Wg/
ml in phosphate-bu¡ered saline (PBS), overnight and at 4‡C. After
washing three times with 50 mM Tris-HCl pH 7.5, 150 mM NaCl,
0.5% (v/v) Tween-20 bu¡er, wells were saturated at room temperature
(RT) for 90 min with 5 mg/ml bovine serum albumin (BSA) in PBS
for the ¢rst and third panning, and 2% non-fat dry milk powder in
PBS for the second panning. Then 1011 phages in washing bu¡er
containing 1% BSA were added for 2 h at RT. After washing 20 times
bound phages were eluted with 0.1 M glycine-HCl pH 2.8 for 10 min
at RT, and neutralized with 2.6 M Tris pH 8.8 (1/20 of the glycine
volume). This procedure was applied for the ¢rst two rounds. Between
each round, eluted phages were ampli¢ed in Escherichia coli strain
ER2537 in liquid medium or on plates. For the third and last round,
the phages were added to two wells, one coated with the selecting
mAb and the other with an irrelevant control mAb. The elution
was ¢rstly done by competitive elution [27] by addition 10 Wg of the
selecting mAb, B-B2 or B-B4, to the microtiter well for 2 h at RT.
Remaining phages were eluted with acidic condition, as for the two
¢rst rounds of selection.
2.3. Sequencing
Phages were randomly picked up after the third selection. Single
strand DNA was prepared and used for sequencing performed with
Sequenase enzyme (Amersham) using 328 gIII or 396 gIII sequenc-
ing primers (Biolabs).
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2.4. ELISA analysis
Wells were coated with peptides (0^100 ng/well) in PBS overnight at
4‡C, and saturated with 5% BSA for 2 h at RT. Three washes were
done between each step. The mAbs B-B2, B-B4 or isotype matched
controls in PBS 1% BSA were added (10^100 ng/well) and incubated
for 2 h at RT. MAb binding was detected with biotinylated goat anti-
mouse Ig (Diaclone) which was incubated for 1 h at RT, then strep-
tavidin horseradish peroxidase (Europa) incubated for 30 min at RT
and ¢nally with TMB substrate (Biosource). Optical density was
measured at 450 nm.
3. Results and discussion
3.1. Epitope identi¢cation
By expression cloning, we previously characterized the anti-
gen recognized by B-B4, a mAb speci¢cally identifying termi-
nally di¡erentiated B-cells among human hemopoietic cells.
Sequencing performed on the isolated clone (H13.7) revealed
that the targeted molecule was syndecan-1. In order to deter-
mine the interacting site of B-B4 mAb, and also of B-B2 mAb
which has a similar reactivity pattern as B-B4 and reacts with
COS cells transfected with H13.f cDNA, we decided to study
the epitopes recognized by B-B2 and B-B4 mAbs with a phage
library displaying random unconstrained peptides composed
of seven residues. Coated mAbs were used to select the phages
which were then eluted with an acidic treatment, and ampli-
¢ed in bacteria for the next round of selection. After the third
round of selection bound phages were ¢rst eluted by adding
the selecting mAb as competitor, and then acidic conditions
were applied to recover the remaining phages. Independently
of the elution procedure used, the number of recovered phages
was at least 30 times higher from the well coated with the
selecting mAb, B-B2 or B-B4 than with an irrelevant control
mAb. These results suggest that the selected phages were mAb
speci¢c. Sequencing was performed on randomly picked
clones and the encoded peptide sequences deduced.
Most of the clones displayed a consensus sequence of four
residues (Table 1), the B-B2 peptide consensus sequence
(QDIT) being di¡erent from that of B-B4 (LPEV). Some
clones align with three amino acids of the consensus sequence,
in the case of B-B2 aspartic amino acid was replaced by its
amide form, asparagine, and in the case of B-B4 glutamic
amino acid was replaced by its amide form, glutamine, or
by aspartic amino acid. The position of the consensus sequen-
ces in the phage displayed peptides is variable for B-B2. For
B-B4, there is at least one amino acid in front of the consen-
sus sequence.
3.2. Epitope location on syndecan-1 core protein
The comparison of the consensus peptide sequences to that
of syndecan-1 enabled us to localize the two epitopes on the
core protein. The B-B2 and B-B4 consensus sequences align
with amino acids 36^39 and 90^93, respectively, of the mature
core protein if the leader sequence is 17 amino acids long (Fig.
1). For some clones the homology is extended. This result is in
agreement with previous experiments showing that B-B2 mAb
did not compete with B-B4 mAb and vice versa for the bind-
ing to cell line U266 (not shown). The B-B2 and B-B4 epitope
sequences have not been found in the known syndecan-1 se-
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Fig. 1. Position of the B-B2 and B-B4 epitopes on the syndecan-1
amino acid sequence. The syndecan-1 hydrophobic sequences corre-
sponding to the leader and transmembrane regions are boxed, the
putative glycosaminoglycan attachment sites are underlined, and the
B-B2 and B-B4 epitopes are boxed in gray.
Fig. 2. ELISA analysis performed with the chemically synthesized
peptides. Di¡erent amounts of B-B2 peptide (A) and B-B4 peptide
(B) were coated on plates. The reactivity of the mAbs was tested
with di¡erent concentrations of B-B2 mAb (IgG2b) and B-B4 mAb
(IgG1), and with isotype matched control mAbs B-E4 (IgG2b) for
B-B2 and B-Z1 (IgG1) for B-B4. The experiments were carried out
in triplicate.
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quences of other organisms, nor in the known sequences of
other members of the human syndecan family.
3.3. Synthetic peptides
Peptides were chemically synthesized in order to con¢rm
the mAb speci¢city. The B-B4 epitope contains three hydro-
phobic amino acids and is £anked by other hydrophobic res-
idues in syndecan-1. To avoid possible problems with solubil-
ity, the chosen sequence for the central part (QLPEVSS) of B-
B4 peptide (SGQLPEVSSGGGC) corresponds to the se-
quence of one of the isolated clones. B-B2 peptide (GALQ-
DITLSQQTC) aligns with the syndecan-1 sequence except for
the last cysteine residue. ELISA analysis showed that B-B2
peptide reacted with B-B2 mAb and B-B4 peptide with B-B4
mAb (Fig. 2). The reactivity of the mAbs for their respective
peptides was dose dependent. B-B2 peptide did not react with
B-B4 mAb (not shown), nor with an irrelevant isotype
matched control mAb (B-E4: IgG2b, Fig. 2A), and B-B4
peptide did not react with B-B2 mAb (not shown), nor with
an irrelevant isotype matched control mAb (B-Z1: IgG1, Fig.
2B). These results correlate with those obtained with the
phages during the third round of selection. They show that
the displayed peptide sequences on the phages interacted with
the respective mAb and that phage environment was dispen-
sable. It is di⁄cult to compare the reactivity of B-B2 and B-
B4 mAbs for their respective peptides since factors such as
coating e⁄ciency and conformations of the coated peptides,
playing a role in the ¢nal results, are not known. Amino acid
preferences for the peptide-plastic interaction are not excluded
and could in£uence the results if such preference concerns
amino acids of the consensus sequences. There are three hy-
drophobic residues in both peptides but all of them are lo-
cated inside the consensus sequence for B-B4 and outside for
B-B2. For example a preference for a hydrophobic interaction
between the peptide and the plastic surface is expected to
lower the a⁄nity of B-B4 mAb for the B-B4 coated peptide.
These mAbs might ¢nd applications in the ¢eld of recombi-
nant protein puri¢cation as such linear epitope sequences can
be introduced into a protein of interest with the recombinant
technology and the expressed proteins can be puri¢ed by af-
¢nity chromatography using the corresponding mAb. By PCR
we introduced the B-B4 epitope at the C-terminus of the ex-
tracellular domain of the L chain of the interferon-Q receptor.
Preliminary results showed that B-B4 mAb reacted with this
modi¢ed protein in an ELISA test (not shown).
3.4. Conclusions
The results show how powerful the peptide phage display
technology is and how speci¢c the mAbs are, since the epito-
pes de¢ned with a library of peptides unrelated to syndecan-1
could be localized on the protein. In both cases the epitope is
linear. These results are in line with the fact that the protein is
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Table 1
Sequence of the peptides encoded by the phages
The shadded lines correspond to syndecan-1 sequences. A sequence found
more than once is followed by the number of identical clones in brackets.
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expected to have an extended conformation deduced from its
high content of proline residues [9] and its abnormal migra-
tion on SDS-PAGE [28]. Both mAbs do not react with post-
translational modi¢cations of syndecan-1 which is known to
be heavily glycosylated. The B-B2 epitope is close to a poten-
tial glycosaminoglycan attachment site. Syndecan-1 glycosyla-
tion is cell type speci¢c, therefore the B-B2 epitope might not
always be as accessible as the B-B4 epitope and this could
explain the di¡erences observed in the reactivity patterns of
the two mAbs [2]. This point has to be investigated to test the
hypothesis.
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